Dr. Tabayoyong is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of the bladder, prostate, and kidney cancers) and advanced open pelvic and retroperitoneal cancer surgery. Dr. Tabayoyong has clinical expertise in all aspects of general urology with special emphasis on the following: Bladder Cancer, Prostate Cancer, Kidney Cancer, Testicular Cancer, Penile Cancer.

Dr. Tabayoyong received his medical degree and PhD in Immunology at the University of Iowa’s Carver College of Medicine Medical Scientist Training Program at the University of Iowa in Iowa City, Iowa in 2011. He completed his urology residency at Case Western Reserve University School of Medicine in Cleveland, Ohio, in 2017. Following residency, he completed a two-year Society of Urologic Oncology fellowship at the University of Texas, MD Anderson Cancer Center in Houston, Texas, in 2019. His research interest is in Immunotherapy for urologic cancers, with primary focus on bladder cancer.

Certified Specialties

Urology - American Board of Urology

Faculty Appointments

Assistant Professor - Department of Urology (SMD)

Credentials

Residency & Fellowship

Fellowship, Urologic Oncology, University of Texas MD Anderson Cancer Center. 2017 - 2019

Residency, Urology, University Hospitals Cleveland Medical Center. 2012 - 2017

Internship, Surgery (General Surgery), University Hospitals Cleveland Medical Center. 2011 - 2012

Education

MD | University Of Iowa Roy J & Lucille A Carver College Of Medicine. 2011

Research

Clinical Trials

A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Lead Researcher: William B Tabayoyong

This study is open-label dose expansion study to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy u...

A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Lead Researcher: William B Tabayoyong

TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-10...

Publications

Journal Articles

Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.

Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM

Urologic oncology.. 2020 October 38 (10):796.e1-796.e6. Epub 05/17/2020.

Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.

Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM

European urology oncology.. 2019 May 2 (3):286-293. Epub 09/10/2018.

Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.

Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM

European urology.. 2019 January 75 (1):8-10. Epub 10/06/2018.

Current Use and Promise of Urinary Markers for Urothelial Cancer.

Tabayoyong W, Kamat AM

Current urology reports.. 2018 October 1719 (12):96. Epub 10/17/2018.

Evaluating the impact of the genitourinary multidisciplinary tumour board: Should every cancer patient be discussed as standard of care?

Scarberry K, Ponsky L, Cherullo E, Larchian W, Bodner D, Cooney M, Ellis R, Maclennan G, Johnson B, Tabayoyong W, Abouassaly R

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2018 September 12 (9):E403-E408. Epub 1900 01 01.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB

European urology focus.. 2018 July 4 (4):512-521. Epub 09/03/2018.

The emerging role of immunotherapy in advanced urothelial cancers.

Tabayoyong W, Gao J

Current opinion in oncology.. 2018 May 30 (3):172-180. Epub 1900 01 01.

Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.

Tabayoyong W, Li R, Gao J, Kamat A

The Urologic clinics of North America.. 2018 May 45 (2):155-167. Epub 02/21/2018.

Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Yu AC, Badve C, Ponsky LE, Pahwa S, Dastmalchian S, Rogers M, Jiang Y, Margevicius S, Schluchter M, Tabayoyong W, Abouassaly R, McGivney D, Griswold MA, Gulani V

Radiology.. 2017 June 283 (3):729-738. Epub 02/10/2017.

Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.

Minnillo BJ, Tabayoyong W, Francis JJ, Maurice MJ, Zhu H, Kim S, Abouassaly R

Canadian Urological Association journal = Journal de l'Association des urologues du Canada.. 2017 May 11 (5):E184-E191. Epub 05/09/2017.

Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses.

Tabayoyong W, Abouassaly R, Kiechle JE, Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC, Zhu H, Ialacci S, Kim SP

The Journal of urology.. 2015 December 194 (6):1548-53. Epub 06/19/2015.

Prostate Cancer Screening and the Associated Controversy.

Tabayoyong W, Abouassaly R

The Surgical clinics of North America.. 2015 October 95 (5):1023-39. Epub 06/23/2015.

Books

Netter's Surgical Anatomy and Approaches (2014)

Chapter: Radical Prostatectomy

Authors: Conor P. Delaney

Publisher: Elsevier, Philadelphia, PA 2014

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.8

Likelihood of recommending this care provider to others

4.8

Explanations the care provider gave you about your problem or condition

4.8

Care provider's efforts to include you in decisions about your care

4.8

Concern the care provider showed for your questions or worries

4.9

Patient Comments

5.0

The medical staff at the Urology Clinic have always been sensitive to and respectful of our needs and concerns. During this visit Dr Tabayoyong quickly picked up on the fact that both my husband (the patient) and I were struggling with his situation. Dr T initiated a much needed difficult and frank discussion of the direction of my husband's care. He listened, was empathetic and made the best possible suggestion for how we should all proceed. And we never felt like he didn't have the time to listen and help. He is just the best.

Feb 02, 2025

5.0

I felt this doctor truly cares; he did not rush the visit & patiently described possible choices of treatment. Made me feel confident of a good outcome w/o "sugarcoating."

Jan 05, 2025

5.0

Good explanations by Urologist Dr. T.

Oct 27, 2024

5.0

Dr. Tabayoyong was wonderful, he listened and then explained what the procedure would be.

Oct 10, 2024

5.0

Very comfortable atmosphere

Aug 30, 2024

5.0

Very satisfied.

Aug 21, 2024

5.0

Excellent Doctor

Jun 20, 2024

3.9

Similar to NP, MD seemed rushed at first, but eventually took time to explain options and show genuine interest in patient care.

May 28, 2024

5.0

All options (medicines), and follow up testing was explained. So far I am very lucky to be in good health for my age.

Apr 26, 2024

5.0

Excellent on all above.

Feb 15, 2024

5.0

It is worth the 2 Hour Dr. to receive good and efficient care from a specialist

Aug 16, 2023

3.0

Would expect dr. to do more explanations & tell another person to go in with many questions. Very LIMITED time.

Jun 01, 2023

5.0

Good

May 20, 2023

5.0

Dr. T was was not only knowledgeable, but patient and thorough in communicating with me.

Mar 31, 2023

5.0

Immediately hit me with the possibility of Cancer. Would've been better to discuss the Best Case Scenario first

Mar 24, 2023

5.0

Again I am very pleased with Dr. Tabayoyong. He is outstanding

Mar 13, 2023

5.0

Doctor seemed rushed to talk and get to next patient.

Mar 01, 2023

5.0

Excellent care.

Jun 22, 2022

5.0

Dr. Tabayoyong was personable and honest with me. I felt at ease with him. He understood my situation and the quality of life decision I made.

Jun 10, 2022

5.0

I commented earlier concerning Dr.Tabayoyong's attention and care

May 26, 2022

Wonderful!

May 12, 2022

5.0

My provider is the best !

May 04, 2022

5.0

Dr. Tabayoyong was very compassionate and very concerned for me. He was nothing less than great.

Apr 19, 2022

Explains everything in details that the patient can understand fully

Mar 03, 2022

5.0

We talked about why I needed a cat scan when I was reluctant to do so and I came to believe that it was very necessary to provide information about cancer of one of the cysts not likely to be cancer but needed to be checked out thoughly which can only be done with a cat scan

Feb 14, 2022